ArticleJournal of cellular and molecular medicine2020
A comprehensive analysis of IDO1 expression with tumour-infiltrating immune cells and mutation burden in gynaecologic and breast cancers.
Article in Journal of cellular and molecular medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 34 citations in OpenAlex.
- Activated immune infiltrates expand opportunities for targeted therapy in p53-abnormal endometrial carcinoma.The Journal of pathology · 2025Article
- Gene signatures derived from transcriptomic-causal networks stratify colorectal cancer patients for effective targeted therapy.Communications medicine · 2025Article
- Oklahoma nitrone-007 is an effective anticancer therapeutic agent targeting inflammatory and immune metabolism pathways in endometrial cancer.The Journal of pharmacology and experimental therapeutics · 2025Article
- Prognostic significance of the inhibitory-to-stimulatory immune checkpoint ratio in patients with breast cancer.Frontiers in oncology · 2025Article
- Breast cancer metastasis progression is associated with elevated activity of kynurenine monooxygenase and kynureninase.British journal of cancer · 2024Article
- Prognostic and immune correlation of IDO1 promoter methylation in breast cancer.Scientific reports · 2024Article
- Protein ubiquitination in ovarian cancer immunotherapy: The progress and therapeutic strategy.Genes & diseases · 2024Review
- Pathomic model based on histopathological features and machine learning to predict IDO1 status and its association with breast cancer prognosis.Breast cancer research and treatment · 2024Article
- HSA-nanobinders crafted from bioresponsive prodrugs for combined cancer chemoimmunotherapy-anFrontiers in chemistry · 2024Article
- Gene signatures derived from transcriptomic-causal networks stratified colorectal cancer patients for effective targeted therapy.Research square · 2023Article
- Thiosemicarbazide Derivatives Targeting Human TopoIIα and IDO-1 as Small-Molecule Drug Candidates for Breast Cancer Treatment.International journal of molecular sciences · 2023Article
- Exosome-Associated Gene Signature for Predicting the Prognosis of Ovarian Cancer Patients.Journal of immunology research · 2023Article
- The exploration of new biomarkers for oral cancer through the ceRNA network and immune microenvironment analysis.Medicine · 2022Article
- Relationship between consolidation tumor ratio and tumor-infiltrating lymphocytes in small-sized lung adenocarcinoma.Thoracic cancer · 2022Article
- Ezrin Regulates the Cell Surface Localization of PD-L1 in HEC-151 Cells.Journal of clinical medicine · 2022Article
- Article
- Dysregulated tumor-associated macrophages in carcinogenesis, progression and targeted therapy of gynecological and breast cancers.Journal of hematology & oncology · 2021Review
- Inactivating Mutations of theCancers · 2021Article
- A systematic analysis of a potential metabolism-related prognostic signature for breast cancer patients.Annals of translational medicine · 2021Article
- Tumor mutation burden in connection with immune-related survival in uterine corpus endometrial carcinoma.Cancer cell international · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gynaecologic and breast cancers share some similarities at the molecular level. The aims of our study are to highlight the similarities and differences about IDO1, an important immune-related gene in female cancers. The NGS data from TCGA of cervical squamous cell carcinoma (CESC), ovarian serous cystadenocarcinoma (OV), uterine corpus endometrial carcinoma (UCEC), uterine carcinosarcoma (UCS) and breast invasive carcinoma (BRCA) were analysed to identify molecular features, and clinically significant and potential therapeutic targets of IDO1. We found IDO1 was significantly up-regulated in four gynaecologic cancers and breast cancer. According to breast cancer PAM50 classification scheme, IDO1 expression was higher in tumours of basal than other subtypes and showed better survival prognosis in BRCA and OV. Through immune infiltration analysis, we found a strong correlation between IDO1 and immune cell populations especially for dendritic cells and T cells. In addition, we investigated the association between IDO1 and tumour mutation burden (TMB) and found that IDO1 was significantly correlated with TMB in BRCA and CESC. GSVA revealed that hallmarks significantly correlated with IDO1 were involved in interferon gamma response, allograft rejection and inflammatory response. We also found PD-L1 and LAG3 were highly positive related to IDO1 in gynaecologic cancers when comparing with their corresponding normal tissues. Our results indicated that IDO1 participated in anti-tumour immune process and is correlated with mutation burden. These findings may expand our outlook of potential anti-IDO1 treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.